Therma Bright Inc V.THRM

Alternate Symbol(s): TBRIF

Technology Scientific & Technical Instruments

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.

TSXV:THRM - Post by User

Therma Bright Inc > FDA EUA Speed of Review in 1st 9 month…

<< Previous

Bullboard Posts

Next >>

Comment by TheeRookon Sep 25, 2021 8:50pm

259 Views

Post# 33920017

RE:FDA EUA Speed of Review in 1st 9 month…

That data is OLD .

September 17, 2021

Testing updates:

As of today, 410 tests and sample collection devices are authorized by the FDA under emergency use authorizations (EUAs). These include 288 molecular tests and sample collection devices, 88 antibody and other immune response tests and 34 antigen tests. There are 62 molecular authorizations that can be used with home-collected samples. There is one molecular prescription at-home test, three antigen prescription at-home tests, seven over-the-counter (OTC) at-home antigen tests, and two OTC molecular tests.
The FDA has authorized 15 antigen tests and eight molecular tests for serial screening programs. The FDA has also authorized 636 revisions to EUA authorizations.

Watchman21 wrote:
More data on FDA & Volume of Covid tests they have reviewed and speed to approval.

As a result of these efforts, by November 1, 2020, FDA had authorized over 285 diagnostic and serology tests, far exceeding the number of test EUAs issued during previous emergencies.